US EditionPublished • loading... • Updated
High cost or insurance-related issues are the most common reasons for discontinuation with semaglutide or tirzepatide
Summary by bariatricnews.net
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
High cost or insurance-related issues are the most common reasons for discontinuation with semaglutide or tirzepatide
High cost or insurance-related issues are the most common reasons for treatment discontinuation with semaglutide or tirzepatide for obesity, according to researchers from Cleveland Clinic, Cleveland, OH. The researchers said the findings highlight the need for policies to address cost and could inform discussions between healthcare providers and patients concerning cost and side effects.This study sought to characterise the reasons for treatment…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
